中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月13日星期天
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (26): 58-62    
  临床研究 本期目录 | 过刊浏览 | 高级检索 |
马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病患者的效果及安全性研究
刘敦炎
 
湖北省广水市第二人民医院消化肾病内科,湖北广水 432721
Study on the efficacy and safety of Trimebutine Maleate combined with Esomeprazole in the treatment of patients with gastroesophageal reflux disease
LIU Dunyan
Department of Gastroenterology and Nephrology, the Second People′s Hospital of Guangshui City, Hubei Province,Guangshui 432721, China
全文: PDF (616 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 
目的 探讨马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病患者的临床效果及安全性。 方法 选取2019年8月至2020年8月广水市第二人民医院消化肾病内科收治的75 例胃食管反流病患者作为研究对象, 采用随机摸球法将其分为观察组(n=38)和对照组(n=37)。 对照组采用埃索美拉唑治疗,观察组采用埃索美拉唑联合马来酸曲美布汀治疗。 比较两组患者的临床疗效,比较两组患者治疗前后的食管远端平滑肌运动功能指标[食管远端收缩积分(DCI)、蠕动性收缩比例、下食管括约肌松弛率(LESRR)和食管下括约肌静息压(LESP)]、胃食管反流病健康相关生存质量量表(GERD-HRQL)评分及胃食管反流病诊断性症状评估量表(GerdQ)评分。 结果 观察组患者的治疗总有效率高于对照组,观察组患者治疗后的LESP、蠕动性收缩比例、LESRR、DCI 均低于对照组,差异有统计学意义(P<0.05)。 观察组患者治疗后的GERD-HRQL 各维度评分、GerdQ 评分均低于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间均未见不良反应。结论 马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病,能提高患者的治疗效果,改善患者食管下段平滑肌运动功能,提高患者生活质量,安全可靠。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘敦炎
关键词 马来酸曲美布汀胃食管反流病埃索美拉唑临床效果    
Abstract
Objective To investigate the clinical efficacy and safety of Trimebutine Maleate combined with Esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Methods A total of 75 patients with gastroesophageal reflux disease admitted to the Department of Gastroenterology and Nephrology of the Second People′s Hospital of Guangshui City from August 2019 to August 2020 were selected as the research subjects, and divided into observation group (n=38) and control group (n=37) by random touch ball method. The control group was treated with Esomeprazole,and the observation group was treated with Esomeprazole and Trammebutine Maleate. The clinical efficacy of the two groups was compared. The motor function indexes of distal esophageal smooth muscle (distal contraction integral [DCI],perperistaltic contraction ratio, lower esophageal sphincter relaxation ratio [LESRR] and low esophageal sphincter pressure [LESP]), gastroesophageal reflux disease health-related quality of life scale (GERD-HRQL) and gastroesophageal reflux disease quality scale (GerdQ) scores were compared between the two groups before and after treatment. Results The total effective rate of the observation group after treatment was higher than that of the control group, and the LESP,perperistaltic contraction ratio, LESRR and DCI of the observation group after treatment were all lower than those of the control group, with statistically significant differences (P<0.05). The GERD-HRQL scores of each dimension of the observation group after treatment were lower than those of the control group, and the GerdQ score of the observation group after treatment was lower than that of the control group, with statistically significant differences (P<0.05). There was no adverse reaction in the two groups during treatment. Conclusion Trimebutine Maleate combined with Esomeprazole can improve the therapeutic effect of patients with gastroesophageal reflux disease, improve the smooth muscle movement function of patients with lower esophagus, and improve the symptoms and quality of life of patients,which is safe and reliable.
Key wordsTrimebutine Maleate    Gastroesophageal reflux disease    Esomeprazole    Clinical effect
    
引用本文:   
刘敦炎. 马来酸曲美布汀联合埃索美拉唑治疗胃食管反流病患者的效果及安全性研究[J]. 中国当代医药, 2022, 29(26): 58-62.
LIU Dunyan. Study on the efficacy and safety of Trimebutine Maleate combined with Esomeprazole in the treatment of patients with gastroesophageal reflux disease. 中国当代医药, 2022, 29(26): 58-62.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I26/58
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载